MCL Literature Feed

This study of Burkitt Lymphoma reveals the key MCL oncogene SOX11 has a context-dependent function, with a transcriptional program and downstream effects differing from its established role in MCL.

A computational, network-based analysis of MCL transcriptomic data identified novel progression pathways, highlighting VEGFA and SPARC as potential drug targets and providing a framework for drug repurposing.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.

This review synthesizes current knowledge on MCL genetic markers, advocating for a personalized medicine approach that integrates molecular profiles like TP53 to improve risk stratification and guide therapy.

This preclinical study identifies a novel cyclin D1 degradation pathway via SUMOylation, showing its disruption causes an MCL-like phenotype and that arsenic trioxide can therapeutically enhance this process.

The SOX11/PRDX2 axis is identified as a key regulator of chemoresistance in aggressive MCL by controlling redox homeostasis, offering a potential new therapeutic target.

This case series characterizes the immunohistochemical and molecular genetic profile of rare lacrimal gland MCL, providing crucial diagnostic insights for this uncommon extranodal presentation.

PRMT5 promotes MCL growth via MYC-driven lipid metabolism reprogramming, identifying it as a poor prognostic marker and a novel therapeutic target with preclinical inhibitor activity.

This case report describes the rare phenomenon of biclonal mantle cell lymphoma, highlighting clonal heterogeneity and evolution which can impact diagnosis, disease progression, and therapeutic resistance.

This preclinical study identifies PLK-1 gene methylation as a key driver of bendamustine resistance, which was reversible with demethylating agents, suggesting a potential new therapeutic strategy.

Transformed MCL with triple-hit genetics (MYC/BCL2/BCL6 rearrangements) can be resistant to BTK inhibitors, identifying a novel genomic mechanism of treatment failure in this aggressive setting.

Gene expression profiling identifies two distinct molecular MCL subtypes, C1 and C2, with C2 showing high proliferation and poor prognosis, providing a powerful new biomarker for risk stratification.

This B-ALL study reveals MALT1 inhibitors downregulate MYC, providing a novel mechanism and strong rationale for testing this strategy in aggressive, MYC-driven mantle cell lymphoma.

This study defines the unique treatment patterns, clinical outcomes, and genomic landscape of Hepatitis B-associated MCL, providing crucial data for managing this complex patient subgroup.

A rare, non-nodal MCL case with hairy cell-like features and a TP53 mutation showed an indolent course, challenging prognostic assumptions and emphasizing comprehensive genomic and pathologic evaluation.

This preclinical study identifies that SOX11 upregulates the antioxidant PRDX2, promoting chemoresistance in aggressive MCL, and suggests PRDX2 as a novel therapeutic target to overcome drug resistance.

MYC overexpression is a critical biomarker defining high-risk mantle cell lymphoma, helping to stratify patients with poor prognosis and potentially guiding novel therapeutic approaches for this aggressive disease.

MCL with concurrent EZH2 expression and TP53 mutation is frequent and identifies a patient subgroup with a dismal outcome, establishing a powerful negative prognostic biomarker combination.

This review summarizes fundamental MCL characteristics, including the t(11;14) translocation and key high-risk features (high Ki67, blastoid variant, TP53 mutation) essential for patient risk stratification.

Mendelian randomization analysis reveals that genetically longer telomeres are a causal risk factor for developing hematological malignancies, including MCL, suggesting a potential inherited predisposition for the disease.

A Mendelian randomization study provides causal evidence that genetically predicted longer telomere length increases the risk of developing MCL, suggesting a role for enhanced cellular proliferation in pathogenesis.

This case report describes an extremely rare pancreatic collision tumor of MCL and adenocarcinoma, hypothesizing a potential role for cyclin D1 in promoting the second malignancy.

This multi-modal single-cell atlas of the human tonsil provides a high-resolution map of normal B-cell development, enabling a deeper understanding of MCL's cellular origins and heterogeneity.

Targeting the epigenetic modifier KDM5 shows preclinical activity in mantle cell lymphoma, identifying a novel therapeutic vulnerability for potential future treatments.

Single-cell analysis reveals the HSP90-MYC-CDK9 network drives sequential BTKi and CAR-T resistance, suggesting co-targeting HSP90 and CDK9 as a novel strategy for dual-refractory MCL.

This workshop report summarizes recent advances in MCL biology and treatment, including BTKi and CAR-T, and outlines key research priorities to overcome resistance and clinical heterogeneity for future progress.

This case report identifies a rare, leukemic, cyclin D1/SOX11-negative MCL driven by a CCND3::IGH rearrangement, highlighting a diagnostic pitfall and the importance of molecular testing in atypical cases.

This preclinical study identifies that the miR-17-92 cluster suppresses the tumor suppressor BTG2, leading to B-cell receptor signaling overactivation and suggesting BTG2 as a prognostic biomarker.

SOX11 expression in cyclin D1-negative large B-cell neoplasms defines them as a variant of blastoid MCL, not DLBCL, solidifying SOX11 as a crucial diagnostic marker for aggressive MCL.

This preclinical study identifies the protease SENP3 as a novel driver of MCL proliferation via the Wnt10a signaling pathway, presenting SENP3 as a potential new therapeutic target.